Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh
{"title":"Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm.","authors":"Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh","doi":"10.5045/br.2023.2023136","DOIUrl":null,"url":null,"abstract":"Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/9b/br-58-3-155.PMC10548284.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
